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Introduction Rheumatic heart disease is still endemic in developing countries and among 
the indigenous population in developed countries. However, there is no 
comprehensive data on rheumatic heart disease patients in Malaysia. The 
Cardiology Department of Queen Elizabeth ll Hospital (QEH ll), Sabah started 
this hospital-based registry in 2010. The objective of this analysis was to report 
the demographic profile, severity of disease, types of valve involvement and 
the practice of secondary prophylaxis among these patients. 
Methods This was a retrospective record review involved a three-year review of patients 
registered under the rheumatic heart disease registry in QEH ll, Sabah from 
December 2010 to November 2013. It included patients who attended the 
cardiology clinic who were diagnosed with rheumatic heart disease.   
Results A total of 627 rheumatic heart disease patients were registered over a period of 
three years. Mean age was 41 (16.2) year old, 67.5% were female, and 51.2% 
of the patients had severe valvular dysfunction with mitral regurgitation as the 
commonest valve affected (67.3%). There was an increasing trend in the 
percentage of patients receiving secondary prophylaxis (oral and intra-
muscular) from the year 2010 to the year 2013 (23.2% and 67.6% 
respectively). Abnormal ECG, pulmonary regurgitation and not on any 
secondary prophylaxis were found to be associated with severe rheumatic heart 
disease. 
Conclusions Rheumatic heart disease is prevalent in Sabah. Most patients had severe form 
of valve dysfunction when diagnosed. Awareness and advocacy on secondary 
prophylaxis warrant immediate improvement. 
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INTRODUCTION 
Rheumatic heart disease (RHD) is a consequence of 
the damage to the heart valves resulting from a 
delayed autoimmune sequel to group A 
streptococcal infections. RHD can become a chronic 
condition leading to congestive heart failure, stroke, 
endocarditis and even death. It is one of the most 
common causes of acquired heart disease among 
children and young adults. Acute rheumatic fever 
(ARF) and RHD continue to be a significant 
contributor to cardiovascular morbidity and 
mortality among young people in developing 
nations. It is estimated that there are over 15 million 
cases of RHD worldwide, with 282,000 new cases 
and 233,000 deaths annually.1 An article published 
in 2011 reported that the incidence of ARF is 
decreasing in all World Health Organization 
Regions except for America and Western Pacific 
where it appears to be in the increasing trend.2 
There is a lack of information on the 
prevalence of RHD in Malaysia, even though it is 
believed that it is common in Malaysia. Earlier 
studies reported several rates. A study on RHD 
among primary school children in Kelantan 
conducted between August 1988 to December 1990 
reported a rate of 0.11 per 1000 population.3 A 10-
year data on paediatric admission in University 
Hospital Kuala Lumpur (1981-1990) reported that 
0.21 per 1000 paediatric admission per year was due 
to ARF.4 However, to date, there is no nationwide 
registry on RHD in Malaysia. It is recommended 
that patient registry is one of the key element of 
RHD control program.5 
The Cardiology Department, in 
collaboration with the Clinical Research Centre, 
Queen Elizabeth ll Hospital, Kota Kinabalu, Sabah 
developed a hospital-based registry to assess the 
burden of RHD in Sabah. This RHD registry was 
developed in 2010. It collects important data on 
patient socio-demographic characteristics, disease 
characteristics and practice patterns. 
This paper presents the demographic 
profile of the RHD patients receiving treatment at 
Queen Elizabeth II Hospital, severity of the disease, 
valve involved and the practice of secondary 
prophylaxis. With this knowledge, we hope to gain 
further insight into the disease burden and 
eventually formulate appropriate preventive 
strategies and collaboration for future research. 
 
 
METHODS 
This was a three year retrospective record review of 
patients registered in the RHD registry of Queen 
Elizabeth ll Hospital, Kota Kinabalu, Sabah from 
December 2010 to November 2013. Queen 
Elizabeth ll Hospital is an adult tertiary government-
funded referral hospital in Sabah, one of the thirteen 
states in Malaysia, with an area of 73,619 km2. The 
state is divided into five administrative division with 
a total population in 2010 was 3.1 million and more 
than 20 ethnic groups.  
All patients who attended the Cardiology 
Clinic and diagnosed with RHD, are enrolled in this 
registry. Patients’ information was extracted from 
the case note and recorded using a data collection 
form. Variables collected included demographic 
profile of the patients namely age, sex, home address 
and ethnicity, current disease status, types of 
secondary prophylaxis medication, ECG changes 
(atrial fibrillation, PR interval and right ventricular 
hypertrophy) and disease extent in term of valves 
abnormality. 
Diagnosis of RHD was made based on 
medical history, physical examination and 
echocardiogram.6 Severity of RHD at diagnosis is 
defined based on World Heart Federation 
Guidelines, into mild, moderate and severe.7 
Patients with congenital heart disease, infective 
endocarditis and whose echocardiogram findings 
not in line with WHF criteria are excluded.  
Data analysis was done using IBM SPSS 
Statistical Software ver 20.0 to provide descriptive 
summaries and make comparisons. Simple and 
multiple logistic regression analysis (using forward 
stepwise method) were used to look for factors 
associated with severe RHD. Statistical significance 
level was considered to be less than 0.05. 
 
RESULTS 
Demographic profiles 
A total of 627 RHD patients were registered over a 
period of three years. More than two thirds, 441 
patients (70.3%) were known case of RHD at 
registration. The demographic profiles of these 
patients are summarized in Table 1. Mean age was 
41 years old with a standard deviation of 16.2 (range 
from 13 to 94 years old). The commonest age group 
was 31–40 years old (Figure 1). There were more 
female (67.5%) and Kadazan-Dusun ethnic group 
(34.0%). Half of the patients, (50.1%) were from the 
West Coast Division as shown in Figure 2. 
 
Table 1 Demographic profiles of RHD patients 
 
Variable Mean (SD) Frequency (%) 
Age at registration 41 (16.2)  
Gender   
          Male  204 (32.5) 
          Female  423 (67.5) 
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Ethnicity   
          Kadazan Dusun  213 (34.0) 
          Bajau  113 (18.0) 
          Malay  49 (7.8) 
          Chinese  86 (13.7) 
          Indian  2 (0.3) 
          Others  164 (26.2) 
 
 
 
Figure 1 Percentage of RHD patients by age group 
 
 
Figure 2 Percentage of patients by division 
 
Severity of disease and type of valve involvement 
In term of patients’ disease status, half of the patients 
(51.2%) had severe form of RHD during enrolment 
into the registry. There was an association between 
severity of disease and status of patient during 
recruitment into this registry (known or new case). 
A total of 73.1% of the new cases were diagnosed as 
severe RHD (Table 2). 
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Table 2 Severity of disease during recruitment 
 
Severity Status at registration p valuea 
 New case Known case  
Mild 34 (18.7%) 148 (34.2%) <0.001 
Moderate 15 (8.2%) 97 (22.4%)  
Severe 133 (73.1%) 188 (43.4%)  
        a Chi-square test for independence 
 
Figure 3 Percentage of patients by types of valve involvement 
Majority of them, 73.7% were diagnosed 
based on clinical presentation. However, 65.4% of 
the patients showed normal sinus rhythm ECG 
pattern. The most common valve abnormality was 
mitral regurgitation (67.3%), followed by aortic 
regurgitation (49.3%) of patients as shown in Figure 
3. 
 
Secondary prophylaxis for RHD 
Figure 4 shows the number of patients receiving 
secondary prophylaxis and type of prophylaxis 
received. 64.7% patients were not on any secondary 
prophylaxis. 19.4% of the patients were on oral 
Penicillin V 250mg twice daily, followed by 15.2% 
who were on IM Benzatine Penicillin G (BPG) 4 
weekly. 
 
Figure 4 Percentage of patients received secondary prophylaxis 
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Table 3 shows that secondary prophylaxis 
given to patients was significantly associated with 
the year of registration and patients’ age group. 
More patients were on IM BPG for prophylaxis in 
2013 (57.7%) compared to the previous three years. 
Majority of the patients who were not on any 
prophylaxis were 40 years old or older (83.9%). 
 
Table 3 Factors associated with practice of secondary prophylaxis 
 
Variable n 
Secondary prophylaxis χ2 statistica (df) P valuea 
None 
n (%) 
Oral 
n (%) 
IM 
n (%) 
Year of registration       
2010 99 76 (76.8) 14 (14.1) 9 (9.1) 123.54 (6) <0.001 
2011 358 249 (69.6) 81 (22.6) 28 (7.8)   
2012 84 48 (57.1) 21 (25.0) 15 (17.9)   
2013 71 23 (32.4) 7 (9.9) 41 (57.7)   
Age group       
Less than 40 295 130 (44.1) 93 (31.5) 72 (24.4) 106.29 (2) <0.001 
Equal or 317 266 (83.9) 30 (9.5) 21 (6.6)   
more than 40       
a Chi-square test for independence 
 
Table 4 and 5 show the results from simple 
logistic regression and multiple logistic regression 
analysis respectively. The significant variables 
associated with severe RHD as compared to mild-
moderate RHD were those RHD patients with 
abnormal ECG readings, presence of pulmonary 
regurgitation and patients who were not on any 
secondary prophylaxis. 
 
Table 4 Factors associated with RHD severity (using simple logistic regression) 
 
Variable Crude OR 95% CI OR χ2 statistica (df)a P valuea 
Age (years) 1.004 (0.994 , 1.014) 0.644 (1) 0.422 
Sex     
Male 1.165 (0.830 , 1.636) 0.784 (1) 0.376 
Female 1.000    
Divisions   0.621 (5) 0.987 
Kudat 0.955 (0.528 , 1.728) 0.023 (1)b 0.880b 
Interior 1.128 (0.687 , 1.850) 0.227 (1)b 0.634b 
Sandakan 0.903 (0.373 , 2.188) 0.051 (1)b 0.822b 
Tawau 0.927 (0.433 , 1.986) 0.038 (1)b 0.846b 
Others 1.277 (0.464 , 3.516) 0.225 (1)b 0.636b 
West Coast 1.000    
Ethnicity   14.091 (4) 0.007 
          Others 0.739 (0.489 , 1.117) 2.059 (1)b 0.151b 
          Malay 1.148 0.612 , 2.154) 0.186 (1)b 0.667b 
          Bajau 1.917 (1.187 , 3.097) 7.075 (1)b 0.008b 
          Chinese 1.117 (0.676 , 1.848) 0.187 (1)b 0.665b 
          Kadazan Dusun 1.000    
Secondary prophylaxis     
Yes 0.670 (0.479 , 0.937) 5.464 (1) 0.019 
No 1.000    
ECG     
Abnormal  1.606  (1.122 , 2.299) 6.698 (1) 0.010 
Normal 1.000    
Valve surgery     
Yes 1.060 (0.764 , 1.472) 0.122 (1) 0.726 
No 1.000    
Pulmonary regurgitation     
Yes 3.132 (1.511 , 6.494) 9.416 (1) 0.002 
No 1.000    
Pulmonary stenosis     
Yes 0.725 (0.193 , 2.727) 0.226 (1) 0.634 
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No 1.000    
Tricuspid regurgitation     
Yes 1.153 (0.833 , 1.596) 0.733 (1) 0.392 
No 1.000    
Tricuspid stenosis     
Yes 1.281 (0.402 , 4.084) 0.176 (1) 0.675 
No 1.000    
Aortic regurgitation     
Yes 1.268 (0.919 , 1.748) 2.095 (1) 0.148 
No 1.000    
Aortic stenosis     
Yes 0.835 (0.542 , 1.285) 0.674 (1) 0.412 
No 1.000    
Mitral regurgitation     
Yes 1.155 (0.821 , 1.626) 0.684 (1) 0.408 
No 1.000    
Mitral stenosis     
Yes 0.709 (0.511 , 0.985) 4.201 (1) 0.040 
No 1.000    
OR = Odds Ratio  a Likelihood Ratio (LR) test b Wald test 
 
 
Table 5 Significant factors associated with RHD severity (using multiple logistic regression) 
 
Variable Adj OR 95% CI OR χ2 statistica (df)a P valuea 
ECG     
Abnormal  1.634  (1.063 , 2.512) 5.016 (1) 0.025 
Normal 1.000    
Pulmonary regurgitation     
Yes 3.751 (1.656 , 8.498) 10.042 (1) 0.002 
No 1.000    
Secondary prophylaxis     
Yes 0.659 (0.442 , 0.982) 4.191 (1) 0.041 
No 1.000    
Adj OR = Adjusted odds ratio a Likelihood Ratio (LR) test 
 
DISCUSSION 
Our results show that RHD is still prevalent in 
Sabah. Mean age of RHD patients who were 
registered in this registry was 41 years old. This is 
comparable to a study in Africa which showed that 
the median age for RHD was 41 years old for 
females and 42 years old for male.8 Another study 
from Australia9 showed that among Aboriginal and 
Torres Strait Islander communities, the highest rates 
of RHD found in adults aged 35-39.9 years. 
However, ARF is commonly reported in children 
between the ages of 6 and 15.10,11 Some of this group 
of children will later on progress to RHD during 
their adulthood. Unlike other cardiovascular 
diseases which is more prevalent among the elderly, 
half of the RHD patients were aged 40 years old or 
less.12  
Majority of the patients were diagnosed 
based on clinical presentations of RHD. Only a few 
of them were diagnosed through systematic 
screening. This is also in concordance that some 
patients were diagnosed with RHD at a later stage of 
the disease. It is reported that, an earlier diagnosis of 
RHD can be achieved through active screening for 
ARF.13 This has not been implemented in Malaysia 
yet. However, regular awareness and advocacy 
drives are given to all attending medical officers in 
our state to improve their knowledge on ARF and 
RHD. 
All four heart valves can be involved in 
rheumatic carditis, however it was reported that 
there is a predominance of mitral valve 
involvement.2 Furthermore, valvular regurgitation is 
frequently the hallmark of rheumatic fever with 
carditis. This pattern was seen among our RHD 
patients too. The commonest type of valve 
involvement was mitral regurgitation, followed by 
aortic regurgitation. Similar findings were observed 
also in studies done in Urban African and Nepal.8, 14 
RHD patients who have recurrences of 
ARF are at risk to develop carditis. Nevertheless, 
this complication is preventable. Secondary 
prophylaxis with 3 to 4 weekly IM BPG can prevent 
recurrences of RF and progression of RHD to more 
severe disease.15, 16 There is ample evidence that this 
strategy is cheap, cost effective and very practical 
especially in developing countries.16 The Australian 
guideline stated that all patients with ARF or RHD 
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should continue secondary prophylaxis for a 
minimum of 10 years after the last episode of ARF, 
or until the age of 21 years (whichever is longer). 
Those with moderate or severe RHD should 
continue secondary prophylaxis up to the age of 35–
40 years.5 This study also supported that those 
patients who were on secondary prophylaxis were 
less likely to have severe disease when other 
variables were controlled in multiple logistic 
regression.  
 This study showed that 35.3% of patients 
were prescribed antibiotics for secondary 
prophylaxis. Most of the patients who did not 
receive secondary prophylaxis were the older 
patients, aged more than 40 years old with less 
vulnerability to the recurrence of RF or to progress 
to more severe disease.16 There was increasing trend 
in percentage of patients being prescribed with IM 
BPG from year 2010 to 2013. This showed a good 
sign and should be continually improved.  
More awareness on RHD should be created 
especially among health care personnel and further 
improvement on its control program should be 
implemented in this country. With continuous 
awareness and advocacy drives, hopefully the 
Ministry of Health will include RHD prevention and 
control program in the National Non Communicable 
Disease in the near future. 
Although it is known that hospital 
morbidity data often give biased information about 
the magnitude of diseases, they are the only 
available data that we can easily capture for the time 
being. Besides the emphasis on the prescription of 
secondary prophylaxis, adherence to secondary 
prophylaxis is of equal importance. The target for 
good adherence to scheduled injections based on 
WHF recommendation on RHD is >80%.7  However 
our registry data does not have record on the 
adherence as yet. Our data originated from one 
single centre in Sabah, and it does not allow 
calculation of exact incidence rates. Furthermore, 
the registry does not comprehensively include all 
RHD cases and may accidentally include non-
rheumatic valvular heart disease as well.  
In conclusion, these data make clear to us 
that ARF and RHD still exist in significant numbers 
around Sabah and need to be taken care of. 
Secondary prophylaxis with IM BPG should be 
enhanced to prevent recurrence and more severe 
disease.  
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